{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:59:08Z","timestamp":1794081548264,"version":"4.8.0"},"reference-count":67,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012632","name":"Nazarbayev University","doi-asserted-by":"crossref","award":["20122022CRP1605"],"award-info":[{"award-number":["20122022CRP1605"]}],"id":[{"id":"10.13039\/501100012632","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW012507"],"award-info":[{"award-number":["D43TW012507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. This study\u2019s objective was to observe the prevalence of HCV genotypes and RAS within the Former Soviet Union (FSU) countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 60 NS3, 313 NS5A and 1119 NS5B sequences of HCV deposited in open-access databases from 11 FSU countries for the prevalence of genotypes and the presence of RAS using the Geno2Pheno software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The following NS3 RASs were revealed through our analyses: 156P\/S\/T, 168del, 80K, 55A and 174S. The most prevalent NS5A RAS was 30K (12.69%) in genotype 3a, associated with resistance to daclatasvir, elbasvir and ledipasvir, followed by 62S (8.96% in genotype 3a), linked with resistance to daclatasvir, and 93H (3.95% and 6.72% in genotypes 1b and 3a, respectively), conferring resistance to daclatasvir, ombitasvir, elbasvir, ledipasvir and velpatasvir. The NS5B RASs found in this study were 451S and 556G, associated with resistance to dasabuvir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2024-001657","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:20:20Z","timestamp":1737667220000},"page":"e001657","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries"],"prefix":"10.1136","volume":"12","author":[{"given":"Aidana","family":"Mustafa","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Davlidova","sequence":"additional","affiliation":[{"name":"Nazarbayev University, Astana, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-0902","authenticated-orcid":false,"given":"Syed Hani","family":"Abidi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Begimbetova","sequence":"additional","affiliation":[{"name":"National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heimer","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten H","family":"Vermund","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-1513","authenticated-orcid":false,"given":"Syed","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2026010701051257000_12.1.e001657.1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i44.4959"},{"key":"2026010701051257000_12.1.e001657.2","doi-asserted-by":"crossref","unstructured":"Hleyhel M , Popovici O , Leu\u0219tean M , et al . Prevalence of chronic hepatitis C infection in the general population: results from a national survey, Romania, 2020 to 2023. Euro Surveill 2024;29. doi:10.2807\/1560-7917.ES.2024.29.30.2300663","DOI":"10.2807\/1560-7917.ES.2024.29.30.2300663"},{"key":"2026010701051257000_12.1.e001657.3","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.2147\/IDR.S363609","article-title":"Epidemiological Characteristics of Chronic Viral Hepatitis in Kazakhstan: Data from Unified Nationwide Electronic Healthcare System 2014-2019","volume":"15","author":"Ashimkhanova","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2026010701051257000_12.1.e001657.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-38853-8","article-title":"The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses","volume":"9","author":"Botheju","year":"2019","journal-title":"Sci Rep"},{"key":"2026010701051257000_12.1.e001657.5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clinre.2019.01.011","article-title":"Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV\/HIV patients in iranian population","volume":"43","author":"Ramezani","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026010701051257000_12.1.e001657.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.6.2057"},{"key":"2026010701051257000_12.1.e001657.7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1099\/0022-1317-78-2-321","article-title":"The origin of hepatitis C virus genotypes","volume":"78 (Pt 2)","author":"Smith","year":"1997","journal-title":"J Gen Virol"},{"key":"2026010701051257000_12.1.e001657.8","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02366-06"},{"key":"2026010701051257000_12.1.e001657.9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026010701051257000_12.1.e001657.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"2026010701051257000_12.1.e001657.11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bjid.2020.06.010","article-title":"Hepatitis C virus genotypes and associated risk factors in the state of Par\u00e1, Northern Brazil","volume":"24","author":"Castro","year":"2020","journal-title":"Braz J Infect Dis"},{"key":"2026010701051257000_12.1.e001657.12","doi-asserted-by":"crossref","DOI":"10.3390\/v14030505","article-title":"Hepatitis C: Standard of Treatment and What to Do for Global Elimination","volume":"14","author":"Di Marco","year":"2022","journal-title":"Viruses"},{"key":"2026010701051257000_12.1.e001657.13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"2026010701051257000_12.1.e001657.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142543","article-title":"Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China\u2019s HIV\/HCV Epidemics","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS ONE"},{"key":"2026010701051257000_12.1.e001657.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.014"},{"key":"2026010701051257000_12.1.e001657.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-018-1100-x","article-title":"Characterization of small genomic regions of the hepatitis B virus should be performed with more caution","volume":"15","author":"Jia","year":"2018","journal-title":"Virol J"},{"key":"2026010701051257000_12.1.e001657.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.02.005"},{"key":"2026010701051257000_12.1.e001657.18","first-page":"103","article-title":"Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens","volume":"25","author":"Wyles","year":"2017","journal-title":"Top Antivir Med"},{"key":"2026010701051257000_12.1.e001657.19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijid.2020.12.068","article-title":"Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review","volume":"104","author":"Davlidova","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026010701051257000_12.1.e001657.20","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.13699","article-title":"Distribution of hepatitis C virus genotypes among azerbaijani patients in capital city of iran-tehran","volume":"13","author":"Bokharaei-Salim","year":"2013","journal-title":"Hepat Mon"},{"key":"2026010701051257000_12.1.e001657.21","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(16)30181-9"},{"key":"2026010701051257000_12.1.e001657.22","unstructured":"CGHE . Data & profiles. 2025. Available: https:\/\/www.globalhep.org\/data-profiles [Accessed 08 Jan 2025]."},{"key":"2026010701051257000_12.1.e001657.23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.36233\/0507-4088-176","article-title":"Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan","volume":"68","author":"Kartashov","year":"2023","journal-title":"Vopr Virusol"},{"key":"2026010701051257000_12.1.e001657.24","doi-asserted-by":"crossref","DOI":"10.3390\/v16091446","article-title":"Seroprevalence of Hepatitis C Virus and Factors Associated with It in Armenia, 2021","volume":"16","author":"Demirchyan","year":"2024","journal-title":"Viruses"},{"key":"2026010701051257000_12.1.e001657.25","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11121482","article-title":"Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia","volume":"11","author":"Pimenov","year":"2022","journal-title":"Pathogens"},{"key":"2026010701051257000_12.1.e001657.26","doi-asserted-by":"publisher","DOI":"10.1007\/BF01718286"},{"key":"2026010701051257000_12.1.e001657.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262935","article-title":"Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey","volume":"17","author":"Baliashvili","year":"2022","journal-title":"PLoS One"},{"key":"2026010701051257000_12.1.e001657.28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7824"},{"key":"2026010701051257000_12.1.e001657.29","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.3748\/wjg.v25.i29.3897","article-title":"Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions","volume":"25","author":"Colombo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2026010701051257000_12.1.e001657.30","doi-asserted-by":"publisher","DOI":"10.2165\/00822942-200504040-00002"},{"key":"2026010701051257000_12.1.e001657.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"key":"2026010701051257000_12.1.e001657.32","doi-asserted-by":"crossref","first-page":"104949","DOI":"10.1016\/j.meegid.2021.104949","article-title":"HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland","volume":"93","author":"Parczewski","year":"2021","journal-title":"Infect Genet Evol"},{"key":"2026010701051257000_12.1.e001657.33","first-page":"12","article-title":"Resistance Associated Mutations in HCV Patients Failing DAA Treatment","volume":"44","author":"Di Stefano","year":"2021","journal-title":"New Microbiol"},{"key":"2026010701051257000_12.1.e001657.34","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9701920","article-title":"Transmission of HIV and HCV within Former Soviet Union Countries","volume":"2020","author":"Aibekova","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2026010701051257000_12.1.e001657.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02687.x"},{"key":"2026010701051257000_12.1.e001657.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31060"},{"key":"2026010701051257000_12.1.e001657.37","unstructured":"\u0420\u0443\u0431\u0440\u0438\u043a\u0430\u0442\u043e\u0440 \u041a\u0420. Available: https:\/\/cr.minzdrav.gov.ru\/schema\/516_2 [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.38","unstructured":"Kazakhstan TMoHotRo . Clinical protocols: chronic hepatitis C infection in adults. 2023. Available: https:\/\/diseases.medelement.com\/disease\/ [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.39","unstructured":"Kyrgyztsan TMoHotRo . \u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430, \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u0438 \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0430 \u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0433\u043e \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0441 > \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u043f\u0440\u043e\u0442\u043e\u043a\u043e\u043b\u044b \u043a\u0440 2017-2020 (\u043a\u044b\u0440\u0433\u044b\u0437\u0441\u0442\u0430\u043d) > [MedElement]. Available: https:\/\/diseases.medelement.com\/disease\/ [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.40","doi-asserted-by":"crossref","DOI":"10.1186\/s41124-017-0026-z","article-title":"Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries","volume":"2","author":"Maistat","year":"2017","journal-title":"Hepatol Med Policy"},{"key":"2026010701051257000_12.1.e001657.41","unstructured":"Ukraine TMoHotRo . Standars of medical management: hepatitis C infection in adults. 2021. Available: https:\/\/moz.gov.ua\/uploads\/5\/28274-dn_51_15_01_2021_dod.pdf [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.42","unstructured":"Hepatitis C disease - symptoms, causes, diagnosis, treatment, prevention. Available: https:\/\/med360.uz\/kasalliklar\/gepatit-c\/#davolash [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.43","unstructured":"Minister of Health of The Republic of Armenia Command . Clinical protocol for the management of hepatitic C virus. Available: https:\/\/www.moh.am\/uploads\/628.pdf [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.44","unstructured":"\u201eC \u10f0\u10d4\u10de\u10d0\u10e2\u10d8\u10e2\u10d8\u10e1 \u10db\u10d0\u10e0\u10d7\u10d5\u10d8\u10e1 \u10e1\u10d0\u10ee\u10d4\u10da\u10db\u10ec\u10d8\u10e4\u10dd \u10de\u10e0\u10dd\u10d2\u10e0\u10d0\u10db\u10d8\u10e1 \u10d3\u10d0\u10db\u10e2\u10d9\u10d8\u10ea\u10d4\u10d1\u10d8\u10e1 \u10e8\u10d4\u10e1\u10d0\u10ee\u10d4\u10d1\u201c \u10e1\u10d0\u10e5\u10d0\u10e0\u10d7\u10d5\u10d4\u10da\u10dd\u10e1 \u10db\u10d7\u10d0\u10d5\u10e0\u10dd\u10d1\u10d8\u10e1 2015 \u10ec\u10da\u10d8\u10e1 20 \u10d0\u10de\u10e0\u10d8\u10da\u10d8\u10e1 \u2116169 \u10d3\u10d0\u10d3\u10d2\u10d4\u10dc\u10d8\u10da\u10d4\u10d1\u10d0\u10e8\u10d8 \u10ea\u10d5\u10da\u10d8\u10da\u10d4\u10d1\u10d8\u10e1 \u10e8\u10d4\u10e2\u10d0\u10dc\u10d8\u10e1 \u10d7\u10d0\u10dd\u10d1\u10d0\u10d6\u10d4. \u10e1\u10e1\u10d8\u10de\u201d\u10e1\u10d0\u10e5\u10d0\u10e0\u10d7\u10d5\u10d4\u10da\u10dd\u10e1 \u10e1\u10d0\u10d9\u10d0\u10dc\u10dd\u10dc\u10db\u10d3\u10d4\u10d1\u10da\u10dd \u10db\u10d0\u10ea\u10dc\u10d4\u201d. Available: https:\/\/matsne.gov.ge\/ka\/document\/view\/4310537 [Accessed 10 Oct 2023]."},{"key":"2026010701051257000_12.1.e001657.45","unstructured":"HepatitC2022. 2022."},{"key":"2026010701051257000_12.1.e001657.46","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01844-18","article-title":"In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3\/4A Inhibitor Voxilaprevir","volume":"57","author":"Han","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026010701051257000_12.1.e001657.47","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02294-12"},{"key":"2026010701051257000_12.1.e001657.48","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12051054","article-title":"Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C","volume":"12","author":"Valutite","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026010701051257000_12.1.e001657.49","doi-asserted-by":"crossref","DOI":"10.3390\/v9080212","article-title":"Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents","volume":"9","author":"Bartolini","year":"2017","journal-title":"Viruses"},{"key":"2026010701051257000_12.1.e001657.50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29693"},{"key":"2026010701051257000_12.1.e001657.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.10.005"},{"key":"2026010701051257000_12.1.e001657.52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102717","article-title":"Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure","volume":"26","author":"Rodrigues","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"2026010701051257000_12.1.e001657.53","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8040080","article-title":"Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C","volume":"8","author":"Kyuregyan","year":"2020","journal-title":"Biomedicines"},{"key":"2026010701051257000_12.1.e001657.54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jve.2022.100071","article-title":"Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China","volume":"8","author":"Liu","year":"2022","journal-title":"J Virus Erad"},{"key":"2026010701051257000_12.1.e001657.55","doi-asserted-by":"crossref","DOI":"10.3390\/v14010016","article-title":"The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures","volume":"14","author":"Popping","year":"2021","journal-title":"Viruses"},{"key":"2026010701051257000_12.1.e001657.56","doi-asserted-by":"crossref","DOI":"10.3390\/v13091832","article-title":"Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients","volume":"13","author":"Di Stefano","year":"2021","journal-title":"Viruses"},{"key":"2026010701051257000_12.1.e001657.57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2021.09.041","article-title":"Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia","volume":"113","author":"Isakov","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026010701051257000_12.1.e001657.58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/apm.13335","article-title":"Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals","volume":"131","author":"S\u00f8lund","year":"2023","journal-title":"APMIS"},{"key":"2026010701051257000_12.1.e001657.59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2019.09.011","article-title":"Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia","volume":"120","author":"Papaluca","year":"2019","journal-title":"J Clin Virol"},{"key":"2026010701051257000_12.1.e001657.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2018.01.004"},{"key":"2026010701051257000_12.1.e001657.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.12.020"},{"key":"2026010701051257000_12.1.e001657.62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP3120","article-title":"Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin","volume":"22","author":"McPhee","year":"2017","journal-title":"Antivir Ther"},{"key":"2026010701051257000_12.1.e001657.63","article-title":"Corrigendum: A novel substitution in NS5A enhances resistance of hepatitis C virus genotype 3 to daclatasvir","volume":"102","author":"Fernandes Campos","year":"2021","journal-title":"J Gen Virol"},{"key":"2026010701051257000_12.1.e001657.64","article-title":"A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir","volume":"102","author":"Fernandes Campos","year":"2021","journal-title":"J Gen Virol"},{"key":"2026010701051257000_12.1.e001657.65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5808\/GI.2012.10.2.117","article-title":"Sample size and statistical power calculation in genetic association studies","volume":"10","author":"Hong","year":"2012","journal-title":"Genomics Inform"},{"key":"2026010701051257000_12.1.e001657.66","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.00535","article-title":"Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China","volume":"10","author":"Lu","year":"2019","journal-title":"Front Microbiol"},{"key":"2026010701051257000_12.1.e001657.67","doi-asserted-by":"crossref","DOI":"10.3390\/v13102096","article-title":"The Role of RASs \/RVs in the Current Management of HCV","volume":"13","author":"Malandris","year":"2021","journal-title":"Viruses"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2024-001657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:05:26Z","timestamp":1767776726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2024-001657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjgast-2024-001657"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2024-001657","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}